Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-Dose and Multiple-Dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2021.04.014
Abstract: PURPOSE For neuropathic pain, current therapies do not provide relief for most patients; less than half achieve a 50% pain reduction. Current analgesics have adverse effects. We present 2 Phase I studies of LX9211, a… read more here.
Keywords: lx9211; controlled studies; placebo controlled; multiple dose ... See more keywords